XBIT
XBiotech Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.00
−5.66%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -60.2%
- EBIT
- -32.0%
- EPS
- -61.3%
- Free cash flow
- -59.1%
- Operating cash flow
- -62.2%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +112.6%
- EPS
- +108.1%
Three-year CAGR
- Revenue
- —
- EBITDA
- -20.9%
- EBIT
- -31.1%
- Net income
- -18.2%
- EPS
- -18.3%
- Free cash flow
- -24.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026